- Stock: In Stock
Available Options
Description
EGFR ELISA Kit
Catalog Number: EGFR-01-1152
Size: 1 plate (96 wells)
EGFR ELISA Kit is a sandwich enzyme-linked immunoassay for
the quantitative determination of EGFR with high sensitivity and specificity in
serum or plasma.
Kit
Performance
- Sensitivity: 30 pg/mL
- Assay Range: 30 – 500 pg/mL
- Cross-reactivity: There is no
cross reaction with native immunoglobulins
- Recovery rate: 80 – 120% with
normal human serum or plasma samples with known concentrations.
- Precision
(CV
(%) = SD/mean X 100)
- Intra-Assay: CV < 20%
- Inter-Assay: CV < 20%
Materials
Supplied
List
of component
|
Components |
Quantity |
|
High binding Plate |
1 plate |
|
EGFR |
1 µg |
|
10x Capture |
700 µL |
|
10x Detection |
700 µL |
|
1x Streptavidin (HRP) (Avoid
light) |
12 mL |
|
1x Plate Coating Buffer |
15 mL |
|
1x Blocking Buffer |
15 mL |
|
2x Assay Diluent |
30 mL |
|
1x TMB Substrate (Avoid light) |
12 mL |
|
1x Stop Solution |
12 mL |
Storage
Instruction
The
components arrive with ice pack, and must immediately be stored at 2-8°C. The
kit components are stable at the date specified in CoA.
Supplementary
information
Epidermal
Growth Factor Receptor (EGFR) is a transmembrane receptor tyrosine kinase that
regulates key cellular processes such as proliferation, survival, and
differentiation.
EGFR
consists of an extracellular ligand-binding domain, a transmembrane region, and
an intracellular tyrosine kinase domain. When ligands such as epidermal growth
factor bind to the receptor, EGFR undergoes dimerization and activates its
kinase activity. This leads to phosphorylation of tyrosine residues on the
receptor, creating docking sites for signaling proteins.
Activated
EGFR initiates several downstream signaling pathways, most notably the
RAS–RAF–MAPK/ERK pathway, which promotes cell proliferation, and the PI3K–AKT
pathway, which supports cell survival and metabolism. Through these pathways,
EGFR signaling regulates gene expression and cellular responses to growth
signals.
Because
of its role in tumor development, EGFR has become an important therapeutic
target. Targeted therapies include small-molecule tyrosine kinase inhibitors
that block EGFR kinase activity and monoclonal antibodies that prevent receptor
activation. EGFR mutation or expression status is therefore often used as a
predictive biomarker to guide treatment selection.